Form 424B3 - Prospectus [Rule 424(b)(3)]
October 29 2024 - 8:15AM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-279539
Prospectus Supplement
(To Prospectus dated
May 31, 2024)
This prospectus supplement supplements and amends the prospectus dated May 31, 2024 (the Prospectus), as supplemented and
amended by that certain prospectus supplement dated July 1, 2024 covering the offering, issuance and sale of up to a maximum aggregate offering price of $6,000,000 of our common stock that may be issued and sold under an Equity Distribution
Agreement with Canaccord Genuity LLC and H.C. Wainwright & Co., LLC (the ATM Facility).
Effective as of
October 29, 2024, we have reduced the maximum aggregate offering price of the ATM Facility to $3,000,000. As of the date of this prospectus supplement, 152,257 shares have been sold under the ATM Facility. All share and per share information
included in this prospectus supplement has been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on October 18, 2024.
You should read this prospectus supplement, together with additional information described under the headings Information Incorporated
by Reference and Where You Can Find Additional Information in the Prospectus carefully before you invest in our securities.
Investing in
our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the risks and uncertainties described in the section entitled Risk Factors beginning on page 5 of the
Prospectus.
The date of this prospectus supplement is October 29, 2024.
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biora Therapeutics (NASDAQ:BIOR)
Historical Stock Chart
From Dec 2023 to Dec 2024